Sayed, Shahin http://orcid.org/0000-0002-3472-511X
Koka, Hela
Abubakar, Mustapha
Gardner, Kevin
Salgado, Roberto
Moloo, Zahir
Caban-Ureña, Ambar Beatriz
Rosen, Daniel
Castro, Patricia
Saleh, Mansoor
Shaikh, Asim Jamal
Shah, Jasmit
Figueroa, Jonine
Makokha, Francis
Ha, Hien Khanh
Wang, Zhong
Magangane, Pumza
Naidoo, Richard
Ngundo, Veronica
Yang, Xiaohong Rose
Govender, Dhirendra
Funding for this research was provided by:
Aga Khan University, East Africa
Division of Cancer Epidemiology and Genetics, National Cancer Institute
Article History
Received: 9 December 2022
Accepted: 17 March 2023
First Online: 3 April 2023
Declarations
:
: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Research Ethics Committees of the Aga Khan University Hospital Nairobi (2016/REC-32 (v3) and the Faculty of Health Sciences Research Ethics Committee of the University of Cape Town (HREC 427/2016). The study was also permitted by the National Commission for Science Technology and Innovation, Kenya (Ref No: NACOSTI/P/19/72237/28785), License number: NACOSTI/P/19/993). The Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) criteria were observed. (McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumour marker prognostic studies. J Clin Oncol 23(36):9067–9072).
: Patient consent was waived due to this being a retrospective study.